Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,297.32
(
-0.06%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

vinmantoo

Send PM Follow Ignore
Followers 28
Posts 4686
Boards Moderated 0
Alias Born 07/25/2007

vinmantoo

Re: DewDiligence post# 236958

Wednesday, 02/03/2021 12:19:57 PM

Wednesday, February 03, 2021 12:19:57 PM

Post# of 257300

ENTA investors appear pleased with ABBV’s $2.0B guidance for 2021 Mavyret sales (#msg-161451655). As has been discussed on this board ad nauseam, Mavyret will not have positive growth, but it should have a long tail.



I am quite pleased that the ENTA cash machine will continue and easily fund the development of NASH, HBV and RSV programs. Yes, and even Covid-19 anti-virals
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today